Oncologists and other clinicians who treat patients with gastrointestinal (GI) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of colorectal, gastric, esophageal, and biliary tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GI cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.
Tumor Board Tuesdays is a bi-weekly, Twitter-based case discussion forum led by expert faculty exploring cases in various GI malignancies. This initiative will help to provide a bridge to extend best treatment practice that will eventually benefit patients and improve outcomes in the management of GI cancers.
Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia
Rachna T. Shroff MD,
Associate Professor of Medicine
University of Arizona Cancer Center
Malvi Savani, MD
Resident/Fellow- College of Medicine
University of Arizona
This program is intended for clinicians involved with, or interested in, the treatment of patients with GI malignancies.
Upon completion of this educational activity, participants will be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of February 23, 2021 through February 23, 2022, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education and Tumor Board Tuesday. Integrity Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
Live Participation on February 23, 2021:
Integrity Continuing Education, Inc. designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation from February 24, 2021 – February 23, 2022:
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Michael L. Pishvaian, MD, PhD
Consulting Fees: Astra Zeneca, Foundation Medicine, Merck
Ownership Interest: Perthera, Inc.
Rachna T. Shroff MD, MS
Consulting Fees: Merck, Seattle Genetics, Exelixis, QED, Debipharm, Agios, Clovis, Incyte
Research: Pieris, Taiho, Rafael Pharmaceuticals
Malvi Savani, MD does not have any conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provided by Integrity Continuing Education, Inc.
Support for this program is provided by Integrity CE.